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Abstract
Induced pluripotent stem cells (iPSCs) derived from somatic cells (SCs) and embryonic stem cells (ESCs) provide promising
resources for regenerative medicine and medical research, leading to a daily identification of new cell lines. However, an
efficient system to discriminate the different types of cell lines is lacking. Here, we develop a quantitative system to
discriminate the three cell types, iPSCs, ESCs, and SCs. The system consists of DNA-methylation biomarkers and
mathematical models, including an artificial neural network and support vector machines. All biomarkers were unbiasedly
selected by calculating an eigengene score derived from analysis of genome-wide DNA methylations. With 30 biomarkers,
or even with as few as 3 top biomarkers, this system can discriminate SCs from pluripotent cells (PCs, including ESCs and
iPSCs) with almost 100% accuracy. With approximately 100 biomarkers, the system can distinguish ESCs from iPSCs with an
accuracy of 95%. This robust system performs precisely with raw data without normalization as well as with converted data
in which the continuous methylation levels are accounted. Strikingly, this system can even accurately predict new samples
generated from different microarray platforms and the next-generation sequencing. The subtypes of cells, such as female
and male iPSCs and fetal and adult SCs, can also be discriminated with this method. Thus, this novel quantitative system
works as an accurate framework for discriminating the three cell types, iPSCs, ESCs, and SCs. This strategy also supports the
notion that DNA-methylation generally varies among the three cell types.
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Introduction
Embryonic stem cells (ESCs) and induced pluripotent stem cells
(iPSCs) provide important resources for regenerative medicine and
medical research [1,2,3,4,5]. Given the potential of these stem cell
lines, an accurate system to discriminate the cell lines is required.
However, such a discriminant system remains to be developed.
Traditionally, biomarkers derived from well-characterized
individual molecules have been used to distinguish somatic cells
(SCs) from pluripotent cells (PCs), including iPSCs and ESCs
[6,7]. PCR and immunostaining can be used to improve the ability
of biomarkers to distinguish SCs from PCs [6]. However,
instabilities within inherent multipotent cell lines due to varying
conditions may produce inaccurate results [7]. For examples, the
OCT4 biomarker, which was once thought to be an excellent
marker for discriminating ESCs from SCs, is only transitionally
expressed in ESCs and is not consistently expressed in different
ESCs, especially in old ESCs [7]. Any single biomarker selected
from a very limited number of samples is unlikely to be robust
enough to classify novel stem cells when applied alone across
different conditions [7]. In addition, most of the current antibody-
based biomarkers will fail to detect low abundance protein signals,
and thus exhibit low sensitivity.
Discriminating ESCs from iPSCs is challenging due to their
similarity. Cluster analysis and meta-analyses of genome-wide
gene expression data sets can circumvent sample size limitations
and generate the unbiased signatures needed to classify ESCs [8].
A combination of linear models and gene expression profiling can
also be used to classify PCs and SCs [9]. However, the gene
signatures cannot be used to distinguish iPSCs and ESCs because
the gene signatures are not consistently expressed across different
cell lines and conditions [10,11]. The gene expression profiling of
iPSCs could be lab-specific when the batch effect was inappro-
priately adjusted [10,12]. Furthermore, linear models and
clustering analyses are associated with a low sensitivity in
determining classification. In addition, they are not the optimal
data classification mode in the presence of an abnormal
distribution and different resources [13]. Thus, the need for a
system that overcomes these challenges and is able to discriminate
all three cell types remains.
In contrast to gene expression, DNA methylation consistently
varies between iPSCs and ESCs under different conditions
[14,15,16]. This suggests that signatures based on DNA methyl-
ation could be used as biomarkers to discriminate iPSCs and
ESCs. In addition, SCs express distinct DNA methylation patterns
compared to PCs [17]. Thus, DNA methylation-based biomarkers
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could provide a promising manner to discriminate among cell
lines.
Applying mathematical models can accurately discriminate
biological samples [12,18,19]. Systems embedded with mathemat-
ical models and trained with large sample sizes can predict
unknown samples. Among mathematical models, artificial neural
network (NNET) [18] and support vector machines (SVM) [20]
are frequently employed in biological discriminations [12]. NNET
is a form of machine learning and non-linear statistical data
modeling which processes data using a connectionism approach
through an interconnected group of artificial neurons [18]. In
most cases, NNET adjusts its structure during the learning phase
according to external or internal information flowing through the
network [18]. Therefore, NNET is able to cope with noisy and
highly dimensional datasets [18]. Similarly, SVM can discriminate
complex samples as we previously reported [12].
In this study we systematically selected biomarkers by an
eigengene score [12], which was calculated from global methyl-
ation profiling, allowing us to establish a quantitative system with
mathematical models (i.e. NNET and SVM) to discriminate
iPSCs, ESCs and SCs.
Results
DNA methylation profiling of iPSCs, ESCs and SCs
To investigate the DNA methylation profiling differentially
expressed in iPSCs, ESCs and SCs, we analyzed genome-wide
microarray profiling of these three cell types. In order to avoid cell-
line-specific DNA methylation signatures and to develop a general
system to discriminate the three cell types, we downloaded and
analyzed a large set of data that contains as various sources as
possible when they are relative to the three cell types (Table S1,
materials and methods). A total of 636 microarrays were used in
this study, including 55% SCs, 18% iPSCs, and 27% ESCs
(Table S1). Various cell sources were included, such as male and
female iPSCs, fetal and adult somatic cells, various tissues,
fibroblasts, iPSC-derived and ESCs-derived somatic cells, fibro-
blast-derived iPSCs, ESCs-somatic cell-derived iPSCs, and
epithelial cell-derived iPSCs.
Unsupervised cluster analysis and correspondence analysis of
these samples revealed that SCs are clearly separated from PCs,
including iPSCs and ESCs. In addition, most ESCs can be
separated from iPSCs (Figure 1A). While SCs are separated from
PCs in the first correspondence component, ESCs were somewhat
different from iPSCs in respect to the correspondence components
2 and 3 (Figure 1B and 1C). This is consistent with the recent
finding that iPSCs express distinct methylation profiling compared
to ESCs [14] and suggests that DNA methylation could be used as
a variable to select biomarkers for distinguishing cell types.
DNA methylation biomarker selection
To improve the quantitative performance of our system, we
selected biomarkers that contribute the most variance in this
system. This ensures that selected biomarkers capture the primary
features of data. Instead of using traditional approaches based on
differential analysis, we employed an eigengene ranking system
derived from principal component analysis (PCA) to circumvent
the correlations of gene methylations [12]. To be conservative and
consistent, we selected biomarkers from one abundant platform
(illumina methylation 27K, GPL8490). The data from other
platforms, including next-generation sequencing, was used for
testing (materials and methods).
We ranked all methylation loci by the eigengene score and
selected the top ,200 methylation sites as biomarkers for each
comparison group (Table 1, Table S2, S3). Interestingly, we
found two groups of biomarkers for discriminating iPSCs from
ESCs. Both groups are important in variance contributions and
they are distributed in two separate PCA components. Biological-
ly, one group is located in autosomes and another in the X-
chromosome (Table S3, S4).
A quantitative system discriminating iPSCs, ESCs and SCs
To establish a quantitative system for discriminating iPSCs,
ESCs and SCs, we employed two types of mathematical models:
artificial neural network (NNET) and support vector machines
(SVM). We ran the above models with our data filtered by
biomarkers. In both models, we measured the percentage of
correction rate and kappa coefficient, which is a statistical measure
of inter-rater agreement for quantitative items.
To determine the optimal biomarker number for discriminating
SCs from PCs, we ran both NNET and SVM by using a series of
marker sets, which follow the order listed in table 1 and Table S2.
In each marker set, all samples were randomly sampled 200 times.
In each run, 70% of random samples worked for training and the
remaining 30% for testing [12] (materials and methods). The
accuracy of the 200 runs for each marker set was calculated.
With approximately 20 markers, both NNET and SVM
discriminated SCs from PCs with an average percentage and
kappa of 1.0 and 1.0, respectively (Figure 2A). Even with 3
markers (cg03273615, cg18201077, cg20217872), both SVM and
NNET could successfully and accurately discriminate these two
cell types with an average percentage and kappa of approximately
1.0 and 1.0, respectively (Figure 2A). After approximately 30
markers were applied, the system achieved a static state. This
stable state suggests that 30 markers might be sufficient to
discriminate SCs from PCs.
Similarly, we also applied the above approach to discriminate
ESCs from iPSCs using two group markers, an autosomal group
and a X-chromosomal group (Table S3, S4). The autosomal
group starts with a 0.75 percentage and 0.4 kappa in both NNET
and SVM. A stable state is reached with a 0.95 percentage and 0.9
kappa with approximately 100 markers (Figure 2B). With 75
markers, the system reaches ,90% accuracy (Figure 2B). The X-
chromosomal group begins with 0.6 percentage and 0.1 kappa and
requires more than 300 markers to reach 87 percentage and 0.6
kappa value. It seemed that more biomarkers are required to reach
higher accuracy and to achieve system stability (Figure S1). Our
study indicated that the autosomal group performed better than x-
chromosomal group and that SVM and NNET performed
similarly in our biomarker sets. Thereafter we used the autosomal
group as the analysis in this study. This result indicates that
discriminating iPSCs and ESCs requires at least 100 biomarkers.
This also suggests that the sample sources of iPSCs and ESCs are
very heterogeneous, leading to the consequence that more
biomarkers (.100) are required to make the system robust and
stable. Together, our system, which includes mathematical models
(SVM and NNET) and DNA methylation markers, can success-
fully discriminate three cell types, SCs, iPSCs, and ESCs. This also
suggests that DNA methylation variations exist among the three
cell types.
The system can be expended for general methylation
measurement
Methylation data measured by traditional experiments like
bisulfite conversion counting are usually presented as a discrete
percentage. Discrete percentages are highly correlated with beta
values that come from microarray data as evidenced by a high
correlation in beta values and percentage methylation levels
Discriminating iPSCs, ESCs and SCs
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measured by genome-wide bisulfite sequencing of ESCs [21]
(Figure 3A). To make our system more applicable to biological
experiments, we converted the beta value to a discrete percentage
level as listed in the following pairs, beta value/percentage .0.90/
100, 0.9/90, 0.85/80, 0.8/70, 0.75/60, 0.7/40, 0.6/25, 0.55/20,
0.5/10, 0.4/5, 0.3/2, 0.17/1, and ,0.17/0.
Using the conversion data, our system has a comparable
performance with unconverted data, and it reaches 100% and
90% accuracy with 30 markers and 100 markers respectively for
discriminating SCs from PCs and iPSCs from ESCs (Figure 3).
The high accuracy with converted and unconverted data suggests
that our system can be used as a generalized application.
Robustness and validation
To further investigate the robustness of this system, we tested
this system using raw data without global normalization (materials
and methods). This system surprisingly works similarly to that with
normalized data. With 30 and 75 markers for discriminating SCs
from PCs and ESCs from iPSCs, our system reaches 100% and
90% accuracy, respectively (Figure 4).
Figure 1. Overall methylation profiling of three cell types. All methylation sites measured by microarray were used to profile the overall
methylation patterns of the three cell types, iPSCs, ESCs, and SCs. A, unsupervised clustering analysis revealed that SCs were separated from PCs
(iPSCs and ESCs). In the PCs subgroup, most ESCs were separated from iPSCs. B, Correspondence analysis classified three cell types, SCs, iPSCs, and
ESCs. SCs and PCs were separated in first component while most of ESCs and iPSCs were separated in second component. C, iPSCs and ESCs were
further classified by correspondence analysis in 3D space. For visualization purposes, only one subset of data was shown here.
doi:10.1371/journal.pone.0056095.g001
Discriminating iPSCs, ESCs and SCs
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We validated this system using different platforms and resources
including data from two new platforms, Illumna 450K
(GPL13534) (materials and methods) and next-generation se-
quencing [16], and data generated by another research group
looking at aging whose focus was unrelated to stem cell research
[22]. The performance of our system was tested on each platform
or resource. In the aging group [22], only SCs are available. All
data was run with at least 20 sets of biomarkers; at least 30 to 50
markers were used for discriminating SCs from PCs and 170 to
200 markers were used for discriminating ESCs from iPSCs
(materials and methods). This system can 100% correctly predict
SCs from PCs under all conditions, while it discriminates ESCs
from iPSCs with ,90% of accuracy (Table 2). The accuracy rates
suggest that this system is very robust and predictive.
Cell subtype discrimination
Distinguished DNA methylation patterns have been observed in
subtypes of cells, such as the subtype of fetal and adult somatic cells
and the subtype of female and male iPSCs [17]. Correspondence
analysis of DNA methylation levels also demonstrated that female
iPSCs clearly separate from male iPSCs (Figure 5A) and adult SCs
separate from fetal SCs (Figure 5B). This suggests that DNA
methylation could be used to select biomarkers for discriminating
cell subtypes. We used the same strategy described above to select
DNA methylation biomarkers for discriminating two subtypes,
iPSCs male and female subtypes and SCs fetal and adult subtypes
(Table S5, S6). Mathematical models with these biomarkers
demonstrated that the accuracy of discriminating female iPSCs
from male iPSCs reaches 100% accuracy when using 2 biomarkers
(Figure 5C, Table S5). When discriminating the adult SCs and
fetal SCs, 95% accuracy is reached with 80 biomarkers
(Figure 5D). The high level of accuracy indicates that our system
could be extended to identify the cell subtypes.
Discussion
For the first time, this study establishes a general quantitative
system based on DNA-methylation markers to discriminate three
cell types, iPSCs, ESCs, and SCs. Conventional methods like the
OCT4 based method to distinguish ESCs from SCs have
limitations and may not be efficient. Currently, there is no way
to discriminate iPSCs from ESCs due to their similarity.
SCs are obviously different from PCs, which include iPSCs and
ESCs. SCs exhibit DNA methylation patterns that can be
distinguished from PCs in all observed conditions thus far
[17,23]. It is therefore reasonable to use DNA methylation as a
variable to discriminate SCs from PCs; however this system does
not exist to date. In contrast, iPSCs closely mimic ESCs in many
aspects such as colony morphology, even gene expressions and
microRNA profiling [1,2,3,4,5,11,24]. Although previous studies
showed that iPSCs generated from single cell resources display
DNA methylation variations compared with ESCs [14,15,23],
these variations could be cell-type specific and condition-depen-
dent due to the limitation of its sample-size and the pure sample-
Table 1. Top biomarker list.
A, top biomarkers for SCs versus PCs
ID Chr MapInfo Symbol Ranking
cg03273615 X 106249029 FLJ11016 0.857614
cg18201077 2 6935238 RSAD2 0.856998
cg20217872 12 76748611 NAV3 0.855689
cg25193278 6 26548763 BTN3A3 0.85371
cg01337047 18 27151111 DSG1 0.852739
cg11009736 2 119416152 MARCO 0.851904
cg05360220 1 2486381 TNFRSF14 0.848173
cg02332073 7 130022959 TSGA13 0.846711
cg04000821 19 59705878 LAIR2 0.84634
cg03791917 X 100527943 BTK 0.845647
B, top biomarkers for ESCs versus iPSCs
ID Chr MapInfo Symbol Ranking
cg09527362 6 74218863 C6orf150 0.891412
cg22736354 6 18230698 NHLRC1 0.88084
cg19005368 11 32808526 PRRG4 0.877542
cg13628514 12 108755822 TRPV4 0.872649
cg08946332 17 6840612 ALOX12 0.871802
cg03699904 3 172228723 SLC2A2 0.871177
cg20019546 7 37922349 SFRP4 0.870126
cg00463577 6 74218632 C6orf150 0.868448
cg00815605 14 73105635 ACOT2 0.868257
cg21233722 5 168997238 DOCK2 0.867968
Left panel, top 10 biomarkers for discriminating SCs from PCs. Right panel, top 10 biomarkers for discriminating iPSCs from ESCs. Please see Table S2, S3, and S4 for
complete list used in this study.
doi:10.1371/journal.pone.0056095.t001
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resources. Here, we collected a large dataset including various cell
line sources and conditions (Table S1) to determine if the DNA
methylation pattern varied between iPSCs and ESCs (Figure 1).
The DNA methylation pattern revealed that iPSCs generally
exhibit certain variations compared to ESCs, regardless of their
originality and conditions. Therefore, DNA methylation could be
used to select biomarkers for discriminating iPSCs from ESCs.
Biomarker selections should consider two major aspects:
generalizability of the sample and method efficiency. Condition-
specific samples [25] like cell-line specific samples [7] could bias
biomarker selections. To make our system generalizable, we
minimized the cell-line bias selection and included various cell line
sources (Table S1), such as different cell originality and gender.
Methods based on differential values are usually employed to
select biomarkers; however, these methods focus only on the
significant differences between variables and fail to avoid variable
correlations and redundant information from the multiple
dimensional microarray data. Thus, these conventional approach-
es could harass biomarker selections [26]. We selected the
biomarkers by adopting the unbiased eigengene selection ap-
proach as we previously reported [12] (materials and methods).
Eigengene-based selection takes care of the variable correlations
Figure 2. Performance of DNA methylation biomarker system. Accuracy was measured as kappa value and accuracy percentage, shown on
the Y-axis. The top panel A represents SCs discriminating from PCs and the bottom panel B represents ESCs from iPSCs. The X-axis represents marker
number, from 1 marker to 50 markers in SCs versus PCs panel (top), and from 1 to 200 markers in ESCs versus iPSCs panel (bottom B). Only data for 50
and 200 markers for these two groups are shown because the system became a static state after that level.
doi:10.1371/journal.pone.0056095.g002
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and the redundant information of multiple variables, and it selects
the independent elements that contribute to most of the variances
in the entire dataset. All conditions like cell originality and other
conditions have been taken into account and variations of
conditions and cell-originalities have been reflected in the variance
contributions. Thus, the selected biomarkers should be the most
generalizable and the most important ones in this system. A
quantitative system based on these selected biomarkers should
perform better than that one based on biomarkers selected from
differential comparisons. Indeed, while not reported here, we
found that a system based on the differential methylation
performed poorer than our system reported here in term of
discriminant accuracy. Therefore, the way that we employed here
to select biomarkers is efficient and the biomarkers selected from
general data including various sources should be of general
properties.
The sensitivity is of most concern for biomarker system
development [7,25,27]. Conventionally, methods based on PCR
or immunochemistry with a single biomarker like OCT4 have
been frequently used in medical researches for distinguishing ESCs
[6,7], but it is unlikely for these traditional approaches to provide a
sensitive system to discriminate all cell types under all conditions
given the substantial heterogeneity among the cell types [7].
Clustering analysis based on gene expression signatures was
proposed to classify ESCs [8]; however its use is severely limited by
the natural low accuracy associated with cluster analysis and the
numerous signatures involved in the clustering. Ideally, a simple
system should be developed, including a small panel of biomarkers
Figure 3. The discriminating system performs precisely on converted data. A, a high correction relationship exists between methylation
percentage measured from sequencing and the beta value measured from Illumina microarray. B, Our system discriminates the three cell types with
high accuracy with converted data. For visualization purposes, only percentage of NNET was shown here due to its similarity with SVM and the high
correlation between accuracy percentage and kappa. This practice was also applied to following figures in this study.
doi:10.1371/journal.pone.0056095.g003
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that are easy measured and a mathematical model that
quantitatively performs a sensitive judgment. However, it is
challenging to assemble and validate such a biomarker panel.
Here, we employed a machine learning system based on NNET
and SVM to systematically and quantitatively validate a panel of
,200 biomarkers for each group (Figure 2). NNET and SVM,
combined with dimension-reduced approaches like principal
component analysis, are advantageous when handling non-linear
functions for nosey multiple dimension data and have been
successfully applied in discriminating disease cell lines and
molecular complexity [12,18]. NNET and SVM with as few as
3 biomarkers for determining SCs from PCs and with 100 markers
for determining iPSCs from ESCs can discriminate the three cell
types with 100% and 95% accuracy respectively for two groups
(Figure 2). This suggests that our system is the most sensitive
system to discriminate the three cell types to date.
Robustness and prediction value are also of concern in
developing discriminant system [7,25,27]. Conventional ap-
proaches such as PCR, immunostaining and clustering analysis
are of low robustness and prediction value. We tested our system
with raw data without normalization and with discrete methyla-
tion percentage data converted from continuous variables
measured from microarray, and we found that our system 100%
and 90% correctly discriminates SCs from PCs and iPSCs from
ESCs, respectively (Figure 3 and Figure 4). When validated by
new samples generated from other independent groups and even
from different microarray platform and next-generation high
throughput sequencing data, our system continued to correctly
predict 100% SCs and 90% of iPSCs from ESCs (Table 2). Thus,
this system established here is very robust and can be generally
applied to discriminate the three cells types in medical research.
Furthermore, Nazor et al. recently revealed the distinguished
DNA methylation patterns existing in the subtypes of cells [17],
such as the subtype of female against male iPSCs, and the subtype
of fetal versus adult SCs. This suggested that DNA methylation
could be used as a variable to discriminate the subtypes of cells.
We extended our system to discriminate the subtypes of cells, and
our system reached 100% accuracy in discriminating female and
male iPSCs with only 2 markers and it got 95% accuracy in
classifying adult and fetal SCs (Figure 5). This indicated that the
DNA methylation difference between female and male iPSCs is so
obvious that we actually do not need more biomarkers to
discriminate them. In contrast, this system requires as many as
80 biomarkers to reach 95% accuracy when discriminating fetal
and adult SCs. Concerning the heterogeneity of SCs, which
contained various tissues with tissue-specific methylation loci [17],
it is reasonable and very promising (95% accuracy) when
discriminating them. Therefore, our system could be reasonably
extended to discriminate other subtypes of cells when more data is
available.
The methylation data for our biomarkers can be measured
using traditional methods, and the measurement is less expensive
than microarray and antibody-based immunochemical approach.
Therefore, the system developed here is a cost effective, accurate
and reliable system to distinguish three cell types. This approach
provides a foundation to develop other discriminant systems.
Figure 4. Our system works accurately with raw data. Our system reaches the similar discriminating power as that with normalized data.
doi:10.1371/journal.pone.0056095.g004










iPSCs SCs vs PCs
0% 1 0.85 1 0.85 1
25% 1 0.87 1 0.88 1
50% 1 0.88 1 0.9 1
75% 1 0.89 1 0.92 1
100% 1 0.91 1 0.93 1
doi:10.1371/journal.pone.0056095.t002
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Materials and Methods
DNA methylation data and processing
All 636 methylation microarray data were downloaded from
GEO database (www.ncbi.nlm.nih.gov/geo/) (Table S1). The
methylation data was preprocessed by GenomeStudio (http://
www.illumina.com/gsp/genomestudio_software.ilmn) and then
processed using R (http://www.r-project.org/). All methylation
values measured by microarray were presented as beta value,
ranging from 0 to 1. Normalizations were performed using
quantile normalization [28]. Before further analysis, outliers were
filtered out by three ways of QC checks, X-chromosome beta
value distribution [29], CpG methylation distribution [28] and the
euclidean distance from samples to the group center. After outliers
were filtered, only 312 out of 399 microarrays generated from the
platform GPL8490 (Illumina 27k) were available for biomarker
selection. Because the microarray data were not generated at the
same time, the batch effect needs to be filtered out before
combining the microarray datasets. An algorithm called ComBat
[30], which runs in R environment and uses parametric and
nonparametric empirical Bayes frameworks to adjust microarray
data for batch effects, was used to adjust the final methylation
values for all datasets.
Figure 5. Cell subtype discrimination. A and B denote correspondence analysis to classify subtypes of cells. A, the subtype of female and male
iPSCs. B, the subtype of fetal and adult SCs. C and D show the accuracy of discriminating subtypes of cells. C, the subtype of female and male iPSCs. D,
the subtype of fetal and adult SCs.
doi:10.1371/journal.pone.0056095.g005
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Biomarker selection
Biomarkers were selected based on an eigengene score, which
was defined below as we previously reported [12].
score~ cor xi,Eð Þj j
|Cor(xi, E)| is the absolute value of Pearson correlation coefficient,
where xi is a vector of methylation of i
th node, and E eigenvalue
derived from principal component analysis.
Artificial neural networks and support vector machines
Mathematical models from NNET packages in R were used to
perform artificial neural network (NNET), with range = 0.1,
decay = 5e-4, and maxit = 200. NNET is machine learning
mathematical model that is designed to emulate the architecture
of the brain [31]. In NNET, data is processed by neurons that are
organized in parallel layers: input, hidden, and output. The
neurons of the input layer receive data as a methylation value and
transmit the input data into the hidden layer neurons that process
the data using mathematical functions. The processed results are
displayed into the output layer neurons. The output neuron with
largest value in output layer will be the group that input neuron
(either iPSCs, ESCs, or SCs) should be.
We used SVM as we previously reported [12]. Briefly, SVM
classifies datasets based on hyperplanes in which samples can be
clustered with the largest separated distances. The R package
e1071 was used in this study. Each run, the parameters were
optimal. The best gamma and best cost, and radial kernel were
finally used for discriminating the test set of samples.
For both NNET and SVM, we randomly sampled 200 times for
each biomarker set, from 1 biomarker to 200 biomarkers, and we
used 70% of the samples as a training set and the remaining 30%
as test data. The accuracy was calculated from the test data set by
measuring both average percentage correct rate and kappa value.
Validation and prediction
During validation and prediction, microarray data were
calculated from 0 to 1 number in beta value format from Illumina
Inc, without removing batch effect and without further normal-
ization. All 27k platform data used for biomarker selections was
treated as training data, and the samples from 45k platform
(GPL13534), the next-generation sequencing [16], and the
samples from the aging study [22] were used as separate testing
sets. The testing samples were randomly sampled 200 times, each
time using 90% of the samples as input for calculating the
accuracy. At least 20 biomarker sets were run for each testing set,
utilizing 30 to 50 markers to determine SCs from PCs and 170 to
200 markers to determine ESCs from iPSCs. Only markers that
overlapped between training and testing data sets were used for
each run. In the sequencing data, we used the read counts from
methylation sites generated from sequencing data that was further
converted them to the range of 0 and 1 in basis of the beta-
percentage relation curve present in figure 3A.
Supporting Information
Table S1 Microarray info. All data were downloaded and the
detail were shown below.
(XLSX)
Table S2 Biomarkers for SCs and PCs. These biomarkers were
selected by score from all filtered array as described in materials
and methods.
(XLS)
Table S3 Biomarkers for ESCs and iPSCs. Please refer to Table
S2.
(XLS)
Table S4 ChrX biomarkers for ESCs and iPSCs. Please refer to
Table S2.
(XLS)
Table S5 Biomarkers for female and male iPSCs. Please refer to
Table S2.
(XLSX)
Table S6 Biomarkers for fetal and adult somatic cells. Please
refer to Table S2.
(XLSX)
Figure S1 Chromosome-X biomarker performance.
Accuracy measured by chromosome-X biomarkers (Table S4).
Two models (NNET and SVM) were used to measure the
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